Cancer 1996, 77:441–451 PubMedCrossRef 14 Vokes EE, Mick R, Kies

Cancer 1996, 77:441–451.PubMedCrossRef 14. Vokes EE, Mick R, Kies MS, Dolan selleck screening library ME, Malone D, Athanasiadis I, Haraf DJ, Kozloff M, Weichselbaum RR, Ratain

MJ: Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol 1996, 14:1663–1671.PubMed 15. Ychou M, Duffour J, Kramar A, Debrigode C, Gourgou S, Bressolle F, Pinguet F: Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. Cancer Chemother Pharmacol 2003, 52:282–290.PubMedCrossRef 16. Milano G, Etienne MC, Renée N, Thyss A, Schneider M, Ramaioli A, Demard F: Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994, 12:1291–1295.PubMed 17. Fety R, Rolland F, Barberi-Heyob M, Hardouin A, Campion L, Conroy T, Merlin JL, Rivière A, Perrocheau G, Etienne MC, Milano G: Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 1998, 4:2039–2045.PubMed 18. Di Paolo A, Lencioni M, Amatori F, Di Donato S, Bocci G, Orlandini C, Lastella M, Federici F, Iannopollo M, Falcone A, Ricci S, Del Tacca M, Danesi R: 5-fluorouracil pharmacokinetics predicts disease-free survival

4SC-202 in patients administered adjuvant chemotherapy for colorectal cancer. Clin Cancer Res 2008, 14:2749–2755.PubMedCrossRef 19. Selleck HM781-36B Beneton M, Chapet S, Blasco H, Giraudeau B, Boisdron-Celle M, Deporte-Fety R, Denis F, Narcisso B, Calais G, Le 4-Aminobutyrate aminotransferase Guellec C: Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy. Br J Clin Pharmacol 2007, 64:613–621.PubMedCrossRef 20. Bocci G, Barbara C, Vannozzi F, Di Paolo A, Melosi A, Barsanti G, Allegrini G, Falcone A, Del Tacca M, Danesi R: A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clin Pharmacol Ther 2006, 80:384–395.PubMedCrossRef 21.

Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, Dorval E, Piot G, Morel A, Boisdron-Celle M: Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:2099–2105.PubMedCrossRef 22. de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH: Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin Pharmacokinet 2005, 44:147–173.PubMedCrossRef 23. Alnaim L: Therapeutic drug monitoring of cancer chemotherapy. J Oncol Pharm Pract 2007, 13:207–221.PubMedCrossRef 24.

Comments are closed.